Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Abstract

Advances in cancer genomics have significantly influenced and improved oncologic treatments in recent years. Somatic genetic testing, which assesses for gene amplification and acquired mutations in tumor tissue, enables the identification of actionable mutations (i.e., biomarkers) to determine patients who may benefit from targeted therapies. Despite the progress made in somatic genetic testing, broad accessibility and adoption have been limited due to multifactorial barriers. Systematically addressing obstacles to somatic genetic testing is required to enhance availability, facilitate cancer treatments, and ultimately improve patient care.